Correlation Between Intellia Therapeutics and Royalty Pharma

Can any of the company-specific risk be diversified away by investing in both Intellia Therapeutics and Royalty Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Intellia Therapeutics and Royalty Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Intellia Therapeutics and Royalty Pharma Plc, you can compare the effects of market volatilities on Intellia Therapeutics and Royalty Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Intellia Therapeutics with a short position of Royalty Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Intellia Therapeutics and Royalty Pharma.

Diversification Opportunities for Intellia Therapeutics and Royalty Pharma

0.84

Correlation Coefficient

Intellia Therapeutics  Royalty Pharma

Very poor diversification

The 3 months correlation between Intellia and Royalty is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Intellia Therapeutics and Royalty Pharma Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Pharma Plc and Intellia Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Intellia Therapeutics are associated (or correlated) with Royalty Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Pharma Plc has no effect on the direction of Intellia Therapeutics i.e., Intellia Therapeutics and Royalty Pharma go up and down completely randomly.

Pair Corralation between Intellia Therapeutics and Royalty Pharma

Given the investment horizon of 90 days Intellia Therapeutics is expected to under-perform the Royalty Pharma. In addition to that, Intellia Therapeutics is 2.82 times more volatile than Royalty Pharma Plc. It trades about -0.08 of its total potential returns per unit of risk. Royalty Pharma Plc is currently generating about -0.02 per unit of volatility. If you would invest  2,742  in Royalty Pharma Plc on September 25, 2024 and sell it today you would lose (250.00) from holding Royalty Pharma Plc or give up 9.12% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	99.6%
Values	Daily Returns

Intellia Therapeutics  vs.  Royalty Pharma Plc

Intellia Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Intellia Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Royalty Pharma Plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Royalty Pharma Plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Intellia Therapeutics and Royalty Pharma

The main advantage of trading using opposite Intellia Therapeutics and Royalty Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Intellia Therapeutics position performs unexpectedly, Royalty Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will offset losses from the drop in Royalty Pharma's long position.

The idea behind Intellia Therapeutics and Royalty Pharma Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.